Africa-focused investment company Tapir Holdings (LON: TAPH) joined AIM on 11 March. Trading in the shares has been limited. Around 15,000 shares have been traded this morning and the share price has risen 15.4% to 37.5p.
Chemotherapy drugs developer CRISM Therapeutics (LON: CRTX) has gained orphan drug designation from the US FDA for irinotecan for the treatment of malignant glioma. This utilises the company’s ChemoSeed technology, which is an implantable, biodegradable technology designed for the localised and sustained delivery of chemotherapy directly into cancer tissue. The orphan drug status will enhance the profile of the commercial development programme. The share price is 14.6% higher at 13.75p.
Atlantic Lithium (LON: ALL) is raising up to £8.2m from Ghanaian investors. There is an initial subscription of £3.7m at 14.6p/share and warrants that could raise a further £4.5m at 21.9p/share. Warrants will be exercisable if the Ewoyaa project reaches certain milestones. There will also tb £4m raised from Long State Investments. The share price increased 11.4% to 15.825p.
Payment services provider Boku (LON: BOKU) increased 2025 revenues by 30% to $128.8m with the main growth coming from digital wallets and bundling. Active users are 31% higher at 114.4 million. Operating profit trebled to £18.9m. The company’s cash increased to £102.9m. The momentum is continuing. Boku intends to repurchase up to 4 million shares. Former boss Jon Prideaux is stepping down from the board. The share price gained 7.9% to 177.5p.
FALLERS
ImmuPharma (LON: IMM) has launched a subscription and retail offer to raise up to £7.5m at 6p/share. ImmuPharma says that there is significant interest from potential licence partners in its autoimmune disease programme P140. Lanstead Capital Investors approached the company to offer further funding for P140 and Kapiglucagon, a form of glucagon that could be used in dual-hormone artificial pancreas devices. The retail offer could raise up to £1.5m of the total fundraising. The share price slipped 22.3% to 5.4p.
Richmond Hill Resources (LON: RHR) says a drone survey of the Martello gold project has been completed. An assessment has been commissioned. A maiden drill programme should folowThe share price fell 20.5% to 1.55p.
A disappointing trading statement from identity management software provider Intercede Group (LON: IGP) has led Cavendish to downgrade forecasts. The company has been hit by disruption to government buying cycles in the US and uncertainty in the Middle East. Cavendish has cut full year forecast revenues from £18.7m to £17m and the pre-tax profit estimate from £4.9m to £4.1m. The share price declined 18% to 79.5p.
Physiomics (LON: PYC) has launched a revised fundraising the day after it received a general meeting request from Michael Whitlow, who owns 13.7%. A placing raised £490,000 at 0.4p/share and a retail offer could raise up to £110,000 more. The original fundraising was at 0.3p/share. Michael Whitlow wants to appoint Nicholas Tulloch, Ian Bagnall, Martin Gouldstone and himself as directors and remove Dr Jim Millen, Shalabh Kumar, Dr Tim Corn, and Dr Peter Sargent, as long as least two of the new directors are appointed. The share price fell 8.6% to 0.425p.
Litigation Capital Management (LON: LIT) says that an Australian court has found against the party funded by the company. So far, A$1.4m has been invested. The next move is being considered. The share price is down 7.81% to 7.79p.